Micrococcin P1 - A bactericidal thiopeptide active against Mycobacterium tuberculosis

Area of Science:

• Microbiology
• Molecular Biology
• Drug Discovery

Background:

• Multidrug resistance in infectious diseases necessitates novel antibiotic development.
• Tuberculosis (TB) presents a significant challenge due to drug-resistant strains and lengthy treatment protocols.
• There is an urgent need for new drugs targeting resistant Mycobacterium tuberculosis.

Purpose of the Study:

• To characterize the thiopeptide micrococcin P1 as a potential anti-tubercular agent.
• To elucidate the mechanism of action of micrococcin P1 against Mycobacterium tuberculosis.
• To identify genetic determinants of micrococcin P1 resistance in M. tuberculosis.

Main Methods:

• Biochemical assays to assess inhibition of protein synthesis.
• Identification and characterization of micrococcin P1-resistant mutations in ribosomal protein L11 (RplK) and 23S rRNA.
• Genetic manipulation to confirm the role of identified mutations in conferring resistance or sensitivity.

Main Results:

• Micrococcin P1 was confirmed to inhibit the elongation step of protein synthesis in mycobacteria.
• Mutations in the ribosomal protein L11 (RplK), specifically in the N-terminal proline loop, conferred resistance to micrococcin P1.
• A mutation in the 23S rRNA gene was also identified as conferring resistance.
• These findings align with structural data suggesting micrococcin P1 binds to a cleft between 23S rRNA and L11, inhibiting elongation factors.

Conclusions:

• Micrococcin P1 is a potent inhibitor of protein synthesis in M. tuberculosis.
• The mechanism involves interference with elongation factors EF-Tu and EF-G by binding to the 23S rRNA-L11 complex.
• Micrococcin P1 represents a promising candidate for the development of new anti-tubercular therapies, particularly against resistant strains.